Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

MPI – VEDTÆGTER

Regulatory

Medical Prognosis Institute A/S – Passing of Extraordinary General Meeting

Regulatory

Medical Prognosis Institute A/S – Forløb af ekstraordinær generalforsamling

Regulatory

MPI – Notice of Extraordinary General Meeting in Medical Prognosis Institute A/S

Regulatory

MPI – Indkaldelse til ekstraordinær generalforsamling i Medical Prognosis Institute A/S

Regulatory

Medical Prognosis Institute A/S – Interim Report First Half 2014

Regulatory

MPI advances the date for publication of its scheduled H1 report for 2014

Non-Regulatory

MPI’s Lung Prognostic Chip study expanded with new gene test – publication of data consequently postponed to H1 2015

Non-Regulatory

MPI and LiPlasome present the phase 1 study with LiPlaCis at the ASCO congress Monday 2 in Chicago at 8am local time

Regulatory

MPI increases its capital by 67,774 shares as a result of the capital increase adopted on the annual general meeting held on 24 April 2014

Regulatory

MPI increases its capital by 21,500 shares as a result of employee warrant exercise

Regulatory

Medical Prognosis Institute A/S – Passing of Annual General Meeting

Regulatory

Medical Prognosis Institute A/S – Forløb af ordinær generalforsamling

Regulatory

Medical Prognosis Institute A/S -Indberetning af ledende medarbejders og nærståendes transaktioner

Regulatory

Notice of Annual General Meeting in Medical Prognosis Institute A/S

Non-Regulatory

MPI and TD2 join in strategic collaboration to provide drug developers a unique Multi Biomarker direct path to drug approval

Non-Regulatory

MPI og TD2 indgår strategisk samarbejde med henblik på at tilbyde udviklere af kræftlægemidler en unik Multi Biomarkør-tilgang til lægemiddelgodkendelse

Regulatory

Medical Prognosis Institute A/S – Annual Report 2013

Regulatory

Medical Prognosis Institute A/S – Årsregnskabsmeddelelse 2013

Non-Regulatory

MPI publishes data showing that MPI’s product DRP may help to identify patients with tumors more likely to respond to fulvestrant